Dementia Blood Test Diagnosis Trial Commences

A new study aiming to pinpoint rapid and precise blood tests for dementia diagnosis is commencing during an “exciting” period for the disease’s treatment, as stated by a prominent scientist. Over 3,800 individuals from 28 NHS memory clinics throughout the UK have received invitations to participate in the five-year Read-Out study, which is being conducted by the University of Oxford. Researchers will evaluate numerous blood tests designed for Alzheimer’s disease and other types of dementia, examining their practicality within clinical environments. Professor Vanessa Raymont, the trial’s lead, indicated that early diagnosis for individuals is gaining significance because novel medications are anticipated “to hit the market very soon”. A component of the research will also investigate the cost-effectiveness of these blood tests and their potential for widespread implementation throughout the NHS. The most precise “gold standard” diagnostic methods for dementia involve PET scans or lumbar punctures; however, merely two per cent of individuals have access to these costly specialized procedures. The majority of patients presently receive diagnoses through memory assessments and brain imaging. Ron Hill, aged 81, residing in Grove, Oxfordshire, received a diagnosis of early dementia following an evaluation at the Oxford Brain Health clinic, situated at the Warneford hospital. He mentioned that approximately three years prior, he began experiencing difficulties with tasks such as discerning the time. “I just couldn’t count, there were situations where I was looking at a clock and I don’t know whether it’s 11:00, 12:00, it wasn’t coming through,” he stated. Mr. Hill intends to participate voluntarily in the trial, aiming to contribute to advancements in dementia diagnosis. Researchers believe that blood tests could facilitate earlier detection of dementia, a point at which therapeutic interventions are most efficacious. In the UK, two novel medications, lecanemab and donanemab, have received licensing; however, they are not accessible via the NHS in England as the health assessment organization NICE determined their benefits were “too small to justify the costs”. Nevertheless, Professor Raymont expresses optimism regarding future prospects: “We’re in a particularly exciting time at the moment, we’ve had the first two new drugs in 20 years licensed for treatment for Alzheimer’s Disease.” “They’re not available on the NHS yet but new drugs are coming that will hopefully hit the market very soon.” The team from Oxford will additionally investigate more convenient alternatives, such as the ability to collect a finger-prick blood sample at home and dispatch it by mail. The study intends to enlist a diverse participant pool, encompassing individuals from minority ethnic communities, the extremely elderly, and those with pre-existing medical conditions. A specific blood test will seek evidence of aberrant proteins in the bloodstream to identify Alzheimer’s disease, which is the most prevalent type of dementia. Other tests will also search for prospective biomarkers associated with vascular and frontotemporal dementia, as well as dementia with Lewy bodies. Investigators will examine if these blood tests are capable of assisting in the detection of these conditions across different stages. This initiative receives backing from Dementias Platform UK and financial support from the Alzheimer’s Society, Alzheimer’s Research UK, the National Institute for Health and Care Research, and Gates Ventures. A separate investigation will concentrate on the most encouraging biomarker for Alzheimer’s disease, aiming to determine if its measurement can elevate the diagnosis rate among individuals with early dementia, as well as those experiencing mild yet progressive memory issues. Readers can connect with BBC Oxfordshire on Facebook, X (Twitter), or Instagram. Copyright 2024 BBC. All rights reserved. The BBC bears no responsibility for the content of external websites. Information regarding our approach to external linking is available.